| Listed site | cro | cro |
|---|
| Summary | Amador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe. | Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries. |
|---|
| Services | - Bioanalysis
- Ligand-Binding Bioanalysis (Large Molecule)
- LC-MS Bioanalysis (Small Molecule)
- Immunogenicity Assays (ADA / NAb)
- Flow Cytometry Services
- Biomarker Assays
- Biostatistics & Statistical Programming
- Translational Research
- Regulatory Affairs
- Clinical Trial Services
- Clinical Operations
- Phase IV / Post-Marketing
| - Discovery Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- Protein Engineering
- Preclinical In Vitro Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Carcinogenicity Studies
- DART (Reproductive & Developmental Toxicology)
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Medical Writing
- Pharmacovigilance & Drug Safety
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Analytical Method Development & Validation
- ICH Stability Studies
- Translational Research
|
|---|
| Modalities | - Antibody-Drug Conjugate (ADC)
- Oligonucleotide
- Peptide
- Small Molecule
- Cell Therapy
- Gene Therapy
- mRNA
- Vaccine
- Biologics (Other)
| - Small Molecule
- Peptide
- Oligonucleotide
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- mRNA
- Cell Therapy
- Gene Therapy
- Vaccine
|
|---|
| Indications | Data not yet provided. | - Oncology
- Immunology
- Neurology
- Psychiatry
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health
|
|---|
| Locations | - California, California, United States
- Maryland, Maryland, United States
- Michigan, Michigan, United States
- Belgium, Belgium
- Hangzhou, Hangzhou, China
- Shanghai, Shanghai, China
- Beijing, Beijing, China
| - Headquarters, Shanghai, Pudong, China
- Global Operations, Asia, Europe, North America
|
|---|
| Certifications | Data not yet provided. | Data not yet provided. |
|---|
| Reviews | Review summary appears after site-level review signal gate opens. | Review summary appears after site-level review signal gate opens. |
|---|